Prothena (PRTA)
(Real Time Quote from BATS)
$25.21 USD
+0.05 (0.20%)
Updated Mar 28, 2024 02:11 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Company Summary
Dublin, Ireland-based Prothena Corporation plc is a late-stage clinical-stage company with a promising pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases.
The company’s wholly-owned programs include birtamimab for the potential treatment of AL amyloidosis and a portfolio of programs for the potential treatment of Alzheimer’s disease (AD), including PRX012, which targets Amyloid beta and PRX123, a novel dual amyloid beta-tau vaccine.
The partnered programs include prasinezumab, in collaboration with Roche, for the potential treatment of Parkinson’s disease and other related synucleinopathies and programs ...
Company Summary
Dublin, Ireland-based Prothena Corporation plc is a late-stage clinical-stage company with a promising pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases.
The company’s wholly-owned programs include birtamimab for the potential treatment of AL amyloidosis and a portfolio of programs for the potential treatment of Alzheimer’s disease (AD), including PRX012, which targets Amyloid beta and PRX123, a novel dual amyloid beta-tau vaccine.
The partnered programs include prasinezumab, in collaboration with Roche, for the potential treatment of Parkinson’s disease and other related synucleinopathies and programs that target tau (PRX005), TDP-43 and an undisclosed target (PRX019), in collaboration with Bristol-Myers Squibb, for the potential treatment of AD, amyotrophic lateral sclerosis (ALS), or other neurodegenerative diseases. The company earns certain potential milestone payments according to its share purchase agreement with Novo Nordisk for its ATTR amyloidosis business.
Prothena’s collaboration with bigwigs like Roche and Bristol-Myers Squibb not only boosts its pipeline development but also provides it with funds in the form of research reimbursement and milestone payments.
Prothena currently does not have any marketed product in its portfolio. The company derives revenues from license, development and commercialization agreements. Revenues in 2023 came in at $91.4 million.
General Information
Prothena Corporation plc
77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS
DUBLIN, L2 D02 VK60
Phone: 011-353-1236-2500
Fax: 353-1902-3510
Email: mark.johnson@prothena.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 12/31/2023 |
Exp Earnings Date | 5/2/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.21 |
Current Year EPS Consensus Estimate | -4.87 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 5/2/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 25.16 |
52 Week High | 79.65 |
52 Week Low | 24.25 |
Beta | 0.22 |
20 Day Moving Average | 578,650.69 |
Target Price Consensus | 67.78 |
4 Week | -13.18 |
12 Week | -33.86 |
YTD | -30.76 |
4 Week | -16.14 |
12 Week | -40.71 |
YTD | -37.08 |
Shares Outstanding (millions) | 53.72 |
Market Capitalization (millions) | 1,351.61 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -1,150.00% |
vs. Previous Quarter | -431.58% |
vs. Previous Year | -99.37% |
vs. Previous Quarter | -99.63% |
Price/Book | 2.41 |
Price/Cash Flow | NA |
Price / Sales | 14.79 |
12/31/23 | -24.84 |
9/30/23 | -12.06 |
6/30/23 | -25.43 |
12/31/23 | -20.24 |
9/30/23 | -9.87 |
6/30/23 | -20.31 |
12/31/23 | 11.24 |
9/30/23 | 12.94 |
6/30/23 | 9.46 |
12/31/23 | 11.24 |
9/30/23 | 12.94 |
6/30/23 | 9.46 |
12/31/23 | -160.91 |
9/30/23 | -51.92 |
6/30/23 | -244.45 |
12/31/23 | -160.91 |
9/30/23 | -51.92 |
6/30/23 | -244.45 |
12/31/23 | -175.64 |
9/30/23 | -61.37 |
6/30/23 | -266.80 |
12/31/23 | 10.46 |
9/30/23 | 11.50 |
6/30/23 | 10.86 |
12/31/23 | NA |
9/30/23 | NA |
6/30/23 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |
6/30/23 | 0.00 |
12/31/23 | 0.00 |
9/30/23 | 0.00 |
6/30/23 | 0.00 |